marketnetra
Sign inStart free

Nephrocare Health Services Limited

NSE: NEPHROPLUSHealthcare

Nephrocare Health Services Limited Share Price & Analysis

₹628.40−0.98%Updated 28 Oct 2026, 03:30 pm IST
LTP
₹628.40−0.98%
Open
₹630.00
High
₹637.90
Low
₹625.70
Close
₹628.40
52W High
₹782.00
52W Low
₹445.00
Volume
59K
Lot Size
1
Sector
Healthcare
Market Cap
₹6K Cr
Face Value
₹2
Mid Cap

Price Chart

Candle
Range

Fundamentals

P/E
70.50
Sector P/E
50.20
P/B
1.69
EPS
₹8.08
ROE
8.83%
ROCE
15.30%
D/E Ratio
0.07
Div Yield
0.00%
Book Value
₹111.00

Strengths

  • Efficient capital deployment (ROCE 15.3%)
  • Virtually debt-free

Concerns

    Peer Comparison

    CompanyCMPMkt CapP/EP/BROE %ROCE %D/E
    SUNPHARMA
    Sun Pharmaceutical Industries Limited
    ₹1,758
    		₹4.2L Cr33.25.051620.50.07
    DIVISLAB
    Divi's Laboratories Limited
    ₹9,559
    		₹2.4L Cr79.815.1516.5220.01
    TORNTPHARM
    Torrent Pharmaceuticals Limited
    ₹4,557
    		₹1.7L Cr79.39.4327.415.20.77
    ZYDUSLIFE
    Zydus Lifesciences Limited
    ₹1,176
    		₹1.1L Cr23.14.3721.221.10.38
    APOLLOHOSP
    Apollo Hospitals Enterprise Limited
    ₹8,137
    		₹1.1L Cr52.812.3521.217.40.88
    CIPLA
    Cipla Limited
    ₹1,366
    		₹1.1L Cr30.23.2111.615.50.01
    LAURUSLABS
    Laurus Labs Limited
    ₹2,182
    		₹1.1L Cr97.422.2218.317.80.46

    Showing 7 peers in the same sector · Sorted by market cap

    Shareholding Pattern

    NEPHROPLUS · as of Sep 2026

    Promoters58.32%5.53pp
    FII11.73%2.95pp
    DII8.11%0.94pp
    Public21.85%3.55pp
    CategoryDec 2025Mar 2026Jun 2026Sep 2026
    Promoters63.85%63.85%63.85%58.32%
    FII9.30%9.94%8.78%11.73%
    DII8.10%8.64%9.05%8.11%
    Public18.74%17.56%18.30%21.85%

    Corporate Events

    To consider and approve the financial results for the period ended Jun 30, 2026

    Results10 Aug 2026

    Latest News

    All news

    Nephrocare to host analyst and investor meet

    *Nephrocare to host analyst and investor meet* to discuss business updates and strategy. The event aims to enhance transparency and investor engagement. No financial figures or major announcements were disclosed. 📊 *STOCKS:* $NEPHROCA | 🏢 *SECTOR:* Healthcare | #LOWIMPACT #InvestorMeet

    NSE Filing21 Oct
    Low Impact

    Nephrocare to hold analyst and investor meet

    *Nephrocare to hold analyst and investor meet* to discuss business updates and strategy. The event is scheduled as per a recent NSE corporate filing. No financial figures or major announcements were disclosed. This is a routine engagement with institutional investors and analysts. 📊 *STOCKS:* $NEPHROCARE | 🏢 *SECTOR:* Healthcare | #LOWIMPACT #InvestorMeet

    NSE Filing13 Aug
    Low Impact

    Univest analyzes Nephro Care India's valuation and peers

    *Univest releases research on Nephro Care India’s valuation and peer comparison.* The report highlights **P/E of 32x** and **EV/EBITDA of 18x**, positioning it as premium to sector peers. Liquidity and scalability remain key concerns for investors. 📊 *STOCKS:* NEPHROCARE | 🏢 *SECTOR:* CapitalMarkets | #LOWIMPACT #Valuation

    Univest9 Sept
    Low Impact

    Financials

    Quarterly Results

    MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
    Revenue
    ₹282 Cr
    6.0%
    ₹266 Cr
    2.3%
    ₹260 Cr
    5.7%
    ₹246 Cr
    7.9%
    ₹228 Cr
    4.1%
    ₹219 Cr
    11.2%
    ₹197 Cr
    Op. Profit
    ₹60 Cr
    17.6%
    ₹51 Cr
    16.4%
    ₹61 Cr
    4.7%
    ₹64 Cr
    33.3%
    ₹48 Cr
    5.9%
    ₹51 Cr
    15.9%
    ₹44 Cr
    OPM
    21.0%
    10.5%
    19.0%
    17.4%
    23.0%
    11.5%
    26.0%
    23.8%
    21.0%
    8.7%
    23.0%
    4.5%
    22.0%
    Net Profit
    ₹32 Cr
    6.7%
    ₹30 Cr
    6.3%
    ₹32 Cr
    455.6%
    ₹-9 Cr
    137.5%
    ₹24 Cr
    4.0%
    ₹25 Cr
    25.0%
    ₹20 Cr
    EPS (₹)
    3.19
    5.3%
    3.03
    5.6%
    3.21
    161.3%
    -5.24
    140.0%
    13.1
    89.0%
    119.3
    23.6%
    96.5

    Values in ₹ Cr · Source: Screener.in

    Annual Profit & Loss

    MetricMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
    Revenue
    ₹999 Cr
    32.1%
    ₹756 Cr
    33.6%
    ₹566 Cr
    29.5%
    ₹437 Cr
    37.4%
    ₹318 Cr
    11.2%
    ₹286 Cr
    Expenses
    ₹774 Cr
    31.4%
    ₹589 Cr
    26.7%
    ₹465 Cr
    19.5%
    ₹389 Cr
    28.8%
    ₹302 Cr
    21.8%
    ₹248 Cr
    Op. Profit
    ₹225 Cr
    34.7%
    ₹167 Cr
    65.3%
    ₹101 Cr
    106.1%
    ₹49 Cr
    206.3%
    ₹16 Cr
    56.8%
    ₹37 Cr
    OPM
    23.0%
    4.5%
    22.0%
    22.2%
    18.0%
    63.6%
    11.0%
    120.0%
    5.0%
    61.5%
    13.0%
    Other Income
    ₹23 Cr
    64.3%
    ₹14 Cr
    75.0%
    ₹8 Cr
    33.3%
    ₹6 Cr
    40.0%
    ₹10 Cr
    100.0%
    ₹5 Cr
    Interest
    ₹60 Cr
    185.7%
    ₹21 Cr
    5.0%
    ₹20 Cr
    25.0%
    ₹16 Cr
    60.0%
    ₹10 Cr
    42.9%
    ₹7 Cr
    Depreciation
    ₹91 Cr
    26.4%
    ₹72 Cr
    28.6%
    ₹56 Cr
    19.1%
    ₹47 Cr
    11.9%
    ₹42 Cr
    23.5%
    ₹34 Cr
    PBT
    ₹97 Cr
    11.5%
    ₹87 Cr
    163.6%
    ₹33 Cr
    466.7%
    ₹-9 Cr
    66.7%
    ₹-27 Cr
    2800.0%
    ₹1 Cr
    Tax %
    21.0%
    8.7%
    23.0%
    483.3%
    -6.0%
    116.2%
    37.0%
    276.2%
    -21.0%
    167.7%
    31.0%
    Net Profit
    ₹77 Cr
    14.9%
    ₹67 Cr
    91.4%
    ₹35 Cr
    391.7%
    ₹-12 Cr
    42.9%
    ₹-21 Cr
    2200.0%
    ₹1 Cr
    EPS (₹)
    7.66
    97.6%
    321.87
    89.5%
    169.82
    389.4%
    -58.69
    45.1%
    -106.93
    3245.0%
    3.4
    Div Payout
    0.0%
    0.0%
    0.0%
    0.0%
    0.0%
    0.0%

    Values in ₹ Cr · Source: Screener.in

    Balance Sheet

    ItemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
    Liabilities
    Equity Capital
    ₹20 Cr
    900.0%
    ₹2 Cr
    0.0%
    ₹2 Cr
    0.0%
    ₹2 Cr
    0.0%
    ₹2 Cr
    0.0%
    ₹2 Cr
    Reserves
    ₹1.1K Cr
    89.3%
    ₹579 Cr
    41.6%
    ₹409 Cr
    6.5%
    ₹384 Cr
    1.8%
    ₹391 Cr
    59.6%
    ₹245 Cr
    Borrowings
    ₹80 Cr
    69.3%
    ₹261 Cr
    3.7%
    ₹271 Cr
    35.5%
    ₹200 Cr
    68.1%
    ₹119 Cr
    15.0%
    ₹140 Cr
    Other Liabilities
    ₹271 Cr
    77.1%
    ₹153 Cr
    23.4%
    ₹124 Cr
    53.1%
    ₹81 Cr
    37.3%
    ₹59 Cr
    40.5%
    ₹42 Cr
    Total Liabilities
    ₹1.5K Cr
    47.6%
    ₹994 Cr
    23.3%
    ₹806 Cr
    21.0%
    ₹666 Cr
    16.6%
    ₹571 Cr
    33.4%
    ₹428 Cr
    Assets
    Fixed Assets
    ₹517 Cr
    30.6%
    ₹396 Cr
    11.2%
    ₹356 Cr
    49.0%
    ₹239 Cr
    16.6%
    ₹205 Cr
    6.8%
    ₹192 Cr
    CWIP
    ₹6 Cr
    0.0%
    ₹6 Cr
    500.0%
    ₹1 Cr
    97.1%
    ₹34 Cr
    20.9%
    ₹43 Cr
    2050.0%
    ₹2 Cr
    Investments
    ₹178 Cr
    249.0%
    ₹51 Cr
    ₹0 Cr
    ₹0 Cr
    ₹0 Cr
    ₹0 Cr
    Other Assets
    ₹767 Cr
    41.5%
    ₹542 Cr
    20.7%
    ₹449 Cr
    14.2%
    ₹393 Cr
    22.0%
    ₹322 Cr
    37.6%
    ₹234 Cr
    Total Assets
    ₹1.5K Cr
    47.6%
    ₹994 Cr
    23.3%
    ₹806 Cr
    21.0%
    ₹666 Cr
    16.6%
    ₹571 Cr
    33.4%
    ₹428 Cr

    Values in ₹ Cr · Source: Screener.in

    Cash Flow Statement

    ItemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
    Operating CF
    ₹233 Cr
    72.6%
    ₹135 Cr
    87.5%
    ₹72 Cr
    554.5%
    ₹11 Cr
    21.4%
    ₹14 Cr
    56.3%
    ₹32 Cr
    Investing CF
    ₹-392 Cr
    213.6%
    ₹-125 Cr
    140.4%
    ₹-52 Cr
    31.6%
    ₹-76 Cr
    41.5%
    ₹-130 Cr
    109.7%
    ₹-62 Cr
    Financing CF
    ₹157 Cr
    190.7%
    ₹54 Cr
    100.0%
    ₹27 Cr
    55.0%
    ₹60 Cr
    50.4%
    ₹121 Cr
    236.1%
    ₹36 Cr
    Net Cash Flow
    ₹-2 Cr
    103.1%
    ₹65 Cr
    38.3%
    ₹47 Cr
    1275.0%
    ₹-4 Cr
    166.7%
    ₹6 Cr
    20.0%
    ₹5 Cr
    Free Cash Flow
    ₹113 Cr
    222.9%
    ₹35 Cr
    537.5%
    ₹-8 Cr
    87.1%
    ₹-62 Cr
    3.1%
    ₹-64 Cr
    120.7%
    ₹-29 Cr

    Values in ₹ Cr · Source: Screener.in

    Key Ratios History

    MetricMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
    Debtor Days
    116d
    10.1%
    129d
    1.5%
    131d
    0.8%
    132d
    7.3%
    123d
    21.8%
    101d
    Inventory Days
    —
    —
    —
    67d
    34.0%
    50d
    23.1%
    65d
    Days Payable
    —
    —
    —
    63d
    10.0%
    70d
    25.0%
    56d
    Cash Conv. Cycle
    116d
    10.1%
    129d
    1.5%
    131d
    4.4%
    137d
    33.0%
    103d
    6.4%
    110d
    Working Capital Days
    42d
    55.6%
    27d
    51.8%
    56d
    194.7%
    19d
    65.5%
    55d
    111.5%
    26d
    ROCE
    15.0%
    7.1%
    14.0%
    75.0%
    8.0%
    700.0%
    1.0%
    125.0%
    -4.0%
    —

    Source: Screener.in · Lower days = better efficiency

    Related Analysis

    Same Sector

    ALKEMAlkem Laboratories LimitedNeutralAPOLLOHOSPApollo Hospitals Enterprise LimitedNeutralAUROPHARMAAurobindo Pharma LimitedNeutralBIOCONBiocon LimitedNeutralCIPLACipla LimitedNeutral

    Frequently Asked Questions

    What is Nephrocare Health Services Limited share price today?
    Nephrocare Health Services Limited (NEPHROPLUS) is currently trading at ₹628.4 on NSE, down 0.98% as of the last market session. Prices update daily after market close on MarketNetra.
    Is Nephrocare Health Services Limited available in F&O (Futures & Options)?
    Yes, Nephrocare Health Services Limited (NEPHROPLUS) is part of the NSE F&O segment with a lot size of 1 shares. Options are available with monthly expiry contracts. You can track the full option chain and OI analysis on MarketNetra.
    What is Nephrocare Health Services Limited 52-week high and low?
    Nephrocare Health Services Limited's 52-week high is ₹782 and the 52-week low is ₹445. The current price of ₹628.4 is 19.6% below the 52W high.
    What is Nephrocare Health Services Limited P/E ratio?
    Nephrocare Health Services Limited's current P/E ratio is 70.5. This indicates the market is paying ₹70.5 for every ₹1 of earnings. Compare this to the sector average to assess relative valuation.
    How to trade Nephrocare Health Services Limited options?
    Nephrocare Health Services Limited options are traded on NSE with monthly expiry contracts (lot size: 1 shares). To trade NEPHROPLUS options: select your expiry on the option chain page, identify key OI strikes, check the PCR and buildup type on OI analysis, and review FII/DII flows for institutional sentiment before taking a position.